-
公开(公告)号：US20200123160A1
公开(公告)日：2020-04-23
申请号：US16538917
申请日：2019-08-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITÉ DE MONTRÉAL
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , C07B59/00 , A61K51/04 , A61K31/55 , A61K31/5386 , A61K31/435 , A61K31/553 , A61K31/541 , A61K31/5377 , A61K31/5025 , A61K31/497 , A61K31/496 , A61K31/454 , A61K31/4439 , A61K31/433 , C07D513/04 , C07D519/00 , A61K45/06
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
Patent Agency Ranking
公开(公告)号：US20180305376A1
公开(公告)日：2018-10-25
申请号：US16020043
申请日：2018-06-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITE DE MONTREAL
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , A61K31/5377 , A61K31/435 , C07D487/04 , A61K31/541 , A61K31/553 , A61K31/433 , A61K31/496 , A61K31/497 , A61K31/454 , A61K45/06 , A61K31/4439 , A61K31/5025 , C07B59/00 , A61K31/55 , A61K51/04 , A61K31/5386 , C07D519/00
CPC classification number: C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US10047103B2
公开(公告)日：2018-08-14
申请号：US15593534
申请日：2017-05-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , C07D487/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/541 , A61K31/553 , A61K31/435 , A61K31/5386 , A61K31/55 , A61K51/04 , C07B59/00
CPC classification number: C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US10428077B2
公开(公告)日：2019-10-01
申请号：US16020043
申请日：2018-06-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITE DE MONTREAL
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , C07D513/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/541 , A61K31/553 , A61K31/435 , A61K31/5386 , A61K31/55 , A61K51/04 , C07B59/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US10822343B2
公开(公告)日：2020-11-03
申请号：US16538917
申请日：2019-08-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITÉ DE MONTRÉAL
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , A61K45/06 , C07D519/00 , C07D513/04 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/541 , A61K31/553 , A61K31/435 , A61K31/5386 , A61K31/55 , A61K51/04 , C07B59/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US20170247395A1
公开(公告)日：2017-08-31
申请号：US15593534
申请日：2017-05-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jaques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestly , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , C07B59/00 , A61K31/433 , A61K31/5377 , A61K31/454 , A61K31/496 , A61K31/4439 , A61K31/497 , A61K31/541 , A61K31/553 , A61K31/5386 , C07D519/00 , A61K31/435 , C07D487/04 , A61K31/5025 , A61K31/55 , A61K51/04
CPC classification number: C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
-
-
-
-
Search Results
6
records
(took 0.028 seconds)
